Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis
This study has been completed.
Study NCT00016458   Information provided by Office of Rare Diseases (ORD)
First Received: May 6, 2001   Last Updated: September 2, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Systemic Sclerosis
Additional conditions recognized in this trial
Scleroderma, Diffuse
Scleroderma, Systemic
Sclerosis
More general conditions related to this trial
Connective Tissue Diseases
Pathologic Processes
Skin Diseases
Interventions listed in this trial
anti-thymocyte globulin
cyclophosphamide
Additional drug interventions recognized in this trial
Antilymphocyte Serum
More general drug interventions related to this trial
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antirheumatic Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Fred Hutchinson Cancer Research Center


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services